These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
116 related articles for article (PubMed ID: 9670610)
1. The emerging role of ricin A-chain immunotoxins in leukemia and lymphoma. Engert A; Sausville EA; Vitetta E Curr Top Microbiol Immunol; 1998; 234():13-33. PubMed ID: 9670610 [TBL] [Abstract][Full Text] [Related]
2. Clinical trials with an anti-CD25 ricin A-chain experimental and immunotoxin (RFT5-SMPT-dgA) in Hodgkin's lymphoma. Schnell R; Vitetta E; Schindler J; Barth S; Winkler U; Borchmann P; Hansmann ML; Diehl V; Ghetie V; Engert A Leuk Lymphoma; 1998 Aug; 30(5-6):525-37. PubMed ID: 9711915 [TBL] [Abstract][Full Text] [Related]
3. The emerging role of immunotoxins in leukemia and lymphoma. Winkler U; Barth S; Schnell R; Diehl V; Engert A Ann Oncol; 1997; 8 Suppl 1():139-46. PubMed ID: 9187448 [TBL] [Abstract][Full Text] [Related]
4. Clinical evaluation of ricin A-chain immunotoxins in patients with Hodgkin's lymphoma. Schnell R; Borchmann P; Staak JO; Schindler J; Ghetie V; Vitetta ES; Engert A Ann Oncol; 2003 May; 14(5):729-36. PubMed ID: 12702527 [TBL] [Abstract][Full Text] [Related]
5. Evaluation of ricin A chain-containing immunotoxins directed against CD19 and CD22 antigens on normal and malignant human B-cells as potential reagents for in vivo therapy. Ghetie MA; May RD; Till M; Uhr JW; Ghetie V; Knowles PP; Relf M; Brown A; Wallace PM; Janossy G Cancer Res; 1988 May; 48(9):2610-7. PubMed ID: 2451562 [TBL] [Abstract][Full Text] [Related]
6. Potent and specific killing of human malignant brain tumor cells by an anti-transferrin receptor antibody-ricin immunotoxin. Zovickian J; Johnson VG; Youle RJ J Neurosurg; 1987 Jun; 66(6):850-61. PubMed ID: 3033171 [TBL] [Abstract][Full Text] [Related]
7. Evaluation of ricin A chain-containing immunotoxins directed against glycolipid and glycoprotein on mouse lymphoma cells. Usui H; Hakomori S Acta Med Okayama; 1994 Dec; 48(6):305-9. PubMed ID: 7709758 [TBL] [Abstract][Full Text] [Related]
8. Successful treatment of human acute T-cell leukemia in SCID mice using the anti-CD7-deglycosylated ricin A-chain immunotoxin DA7. Jansen B; Vallera DA; Jaszcz WB; Nguyen D; Kersey JH Cancer Res; 1992 Mar; 52(5):1314-21. PubMed ID: 1371092 [TBL] [Abstract][Full Text] [Related]
9. Therapy of patients with T-cell lymphomas and leukemias using an anti-CD7 monoclonal antibody-ricin A chain immunotoxin. Frankel AE; Laver JH; Willingham MC; Burns LJ; Kersey JH; Vallera DA Leuk Lymphoma; 1997 Jul; 26(3-4):287-98. PubMed ID: 9322891 [TBL] [Abstract][Full Text] [Related]
10. Phase I trial of H65-RTA immunoconjugate in patients with cutaneous T-cell lymphoma. LeMaistre CF; Rosen S; Frankel A; Kornfeld S; Saria E; Meneghetti C; Drajesk J; Fishwild D; Scannon P; Byers V Blood; 1991 Sep; 78(5):1173-82. PubMed ID: 1878584 [TBL] [Abstract][Full Text] [Related]
12. Immunotoxin therapy of malignant melanoma. Spitler LE Med Oncol Tumor Pharmacother; 1986; 3(3-4):147-52. PubMed ID: 3543527 [TBL] [Abstract][Full Text] [Related]
13. The chronic lymphocytic leukemia antigen (cCLLa) as immunotherapy target: pharmacokinetics and biodistribution of two divalent, ricin-based immunotoxins in xenografted athymic mice. Faguet GB; Agee JF Leuk Lymphoma; 1997 May; 25(5-6):509-20. PubMed ID: 9250822 [TBL] [Abstract][Full Text] [Related]
14. Immunotoxins containing ricin or its A chain. Vitetta ES; Thorpe PE Semin Cell Biol; 1991 Feb; 2(1):47-58. PubMed ID: 1954343 [TBL] [Abstract][Full Text] [Related]
15. A Phase II study of adjuvant therapy with anti-B4-blocked ricin after autologous bone marrow transplantation for patients with relapsed B-cell non-Hodgkin's lymphoma. Grossbard ML; Multani PS; Freedman AS; O'Day S; Gribben JG; Rhuda C; Neuberg D; Nadler LM Clin Cancer Res; 1999 Sep; 5(9):2392-8. PubMed ID: 10499609 [TBL] [Abstract][Full Text] [Related]
16. Immunotoxins in cancer therapy: Review and update. Akbari B; Farajnia S; Ahdi Khosroshahi S; Safari F; Yousefi M; Dariushnejad H; Rahbarnia L Int Rev Immunol; 2017 Jul; 36(4):207-219. PubMed ID: 28282218 [TBL] [Abstract][Full Text] [Related]
17. Recombinant ricin toxin A chain cytotoxicity against carcinoembryonic antigen expressing tumour cells mediated by a bispecific monoclonal antibody and its potentiation by ricin toxin B chain. Embleton MJ; Charleston A; Robins RA; Pimm MV; Baldwin RW Br J Cancer; 1991 May; 63(5):670-4. PubMed ID: 2039690 [TBL] [Abstract][Full Text] [Related]
18. Cell surface density of p185(c-erbB-2) determines susceptibility to anti-p185(c-erbB-2)-ricin A chain (RTA) immunotoxin therapy alone and in combination with anti-p170(EGFR)-RTA in ovarian cancer cells. Dean GS; Pusztai L; Xu FJ; O'Briant K; DeSombre K; Conaway M; Boyer CM; Mendelsohn J; Bast RC Clin Cancer Res; 1998 Oct; 4(10):2545-50. PubMed ID: 9796989 [TBL] [Abstract][Full Text] [Related]
19. Development of new ricin A-chain immunotoxins with potent anti-tumor effects against human Hodgkin cells in vitro and disseminated Hodgkin tumors in SCID mice using high-affinity monoclonal antibodies directed against the CD30 antigen. Schnell R; Linnartz C; Katouzi AA; Schön G; Bohlen H; Horn-Lohrens O; Parwaresch RM; Lange H; Diehl V; Lemke H Int J Cancer; 1995 Oct; 63(2):238-44. PubMed ID: 7591211 [TBL] [Abstract][Full Text] [Related]
20. The in vivo anti-tumor activity of immunotoxins containing two versus one deglycosylated ricin A chains. Ghetie V; Engert A; Schnell R; Vitetta ES Cancer Lett; 1995 Nov; 98(1):97-101. PubMed ID: 8529213 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]